A working prototype is not the same thing as a manufacturable product, and the gap between the two is where most medical device schedules quietly fall apart. In eight years of working alongside R&D teams, the pattern is consistent: the technology usually works. The electronics function, the mechanism actuates, the catheter tracks where it should. What derails the program is rarely the core engineering. The assumption is that a bench-built prototype will translate cleanly into a repeatable, cost-controlled production process. Medical device manufacturability has to be evaluated as early as the technology itself, not confirmed after the fact.
This matters more in medical devices than in almost any other industry, because discovering a manufacturability problem late is compounded by design controls and the documentation trail that has to support every change. A tolerance that seemed reasonable in a CAD model can become a yield problem on the line. A connector that was easy to source for a prototype can become a six-month lead-time bottleneck by the time the design is frozen.
None of this means engineers need to become manufacturing experts. It means that design for manufacturability for medical devices needs to be a design input, not a downstream problem to be solved after the fact. The seven questions below are worth asking before a design freeze, not after design transfer has stalled. ClearPath Medical works through exactly these questions with engineering teams every week as part of new product introduction and medical device prototype development, and the goal here is to walk through the reasoning. Hence, it’s useful regardless of who eventually builds the device.
1. Can This Design Be Built at Scale?
A prototype built by a skilled technician, with unlimited time and hand-selected components, will always outperform what a production line can repeat consistently at volume. That gap is the first thing to interrogate honestly.
Fine-gauge wire assemblies are a good example. A 36 AWG lead that a senior technician can strip, tin, and terminate cleanly on the bench may have a much lower first-pass yield when handled by a production operator working to a fixed cycle time. The physics of the wire doesn’t change, but the process’s consistency does. The same is true of connector terminations and any assembly step where success depends heavily on individual skill rather than process control.
Highly complex, labor-intensive assemblies raise a related risk. Every additional manual step, every sub-assembly built and then integrated, is another point where variation and rework can creep in. A design with 40 discrete manual operations isn’t automatically wrong, but it needs an honest look at labor content and cycle time.
A practical test: could this be built by three different, reasonably competent operators and still pass inspection consistently? If the honest answer is “only if it’s one specific person,” the design is relying on a skill dependency rather than a repeatable process. The fix is often small: a strain-relief geometry more forgiving of placement tolerances, a connector housing that keys itself so it can’t be assembled incorrectly, or a wire gauge one step larger that trades a little flex performance for meaningfully better yield.
2. Are We Designing Supply Chain Risk Into the Product?
Component choices made early in development often become permanent, and some quietly build medical device supply chain risk into the product long before anyone notices.
Sole-source components are the most common version of this. A specialty connector or custom-molded overmold material from a single supplier might be the right technical choice. Still, if that supplier has a quality escape or a capacity constraint, the entire product line is exposed. Proprietary connectors, selected because they elegantly solved a mechanical or electrical requirement, deserve extra scrutiny when there’s no functionally equivalent second source.
Long-lead components carry the same risk, particularly electromechanical parts and specialty cable, which can take well over 20 weeks depending on the supply environment. A design that locks in a single long-lead component without a qualified alternative is making a forecasting bet, whether or not that was the intent.
Obsolete materials are a slower-moving version of the same problem. A cable jacket compound or adhesive available today may be discontinued with little warning, and a substitution typically requires a documented equivalency assessment and, depending on classification, additional testing. Global sourcing adds a further layer, since single-region supply of a critical material means that geopolitical or logistical disruption becomes product risk.
A few habits reduce this exposure: identify sole-source components explicitly during design reviews; qualify a second source early, even if it’s never used; and treat sourcing risk as a real factor when comparing a proprietary component to an off-the-shelf equivalent, not an afterthought.
3. What Happens When the Design Changes?
Design changes are normal in medical device development. The real question is how well the organization absorbs a change once it happens, especially if production has already started.
An engineering change order that looks simple- a revised trace width, a new label artwork file- can have a larger blast radius than expected. If work-in-process inventory exists at multiple stages, a manufacturer has to determine what gets scrapped, what gets reworked, and what can ship under the prior revision. If documentation isn’t tightly aligned between the design history file and the manufacturer’s process documentation, a change can be implemented inconsistently across build lots until an audit or nonconformance investigation surfaces it.
Revision control sounds administrative until it isn’t. A manufacturer building to an out-of-date drawing because the latest revision wasn’t communicated promptly is an avoidable failure, and it happens more often than it should, usually because change notifications rely on email rather than a formal, trackable handoff.
The cost and schedule impact of a poorly managed change is rarely just the cost of the change itself. It’s the scrapped inventory, the repeated requalification testing, and the schedule slip while everyone reconciles what was actually built against what should have been built.
The best mitigation isn’t a process document; it’s a working relationship. When engineering and manufacturing stay in regular contact throughout the program, changes get flagged early enough to plan around instead of react to. A manufacturing partner who understands why a change is being made, not just what changed, is more likely to catch a downstream implication the change order itself missed.
4. Have We Fully Considered Packaging and Labeling Requirements?
Packaging is easy to treat as the last step, something finalized once the device is done. That sequencing is a common source of late-stage schedule pain, because medical device packaging validation carries its own verification and validation requirements, separate from the device itself.
UDI requirements and GS1 barcode formatting need to be built into label artwork early, not adapted at the end. Barcode readability may seem minor, but a barcode that scans fine on a lab printer proof can fail readability testing once printed at production scale on the actual label stock, particularly if the material or print method changes between prototype and production runs.
Sterile barrier systems carry their own validation burden. The combination of the tray, pouch, or wrap with the device geometry must maintain sterility throughout the defined shelf life, and validation takes real calendar time. A packaging change made after validation is complete can trigger a partial or full revalidation, which is one of the more common reasons a technically finished device still isn’t shippable.
Human factors belong in this conversation too. Can the intended user open the package without contaminating the sterile field, with the peel force appropriate for a clinical setting under time pressure? These are usability questions as much as packaging questions, and far cheaper to answer with a mockup during development than with a corrective action after launch.
The practical takeaway: bring packaging into the design conversation alongside the device, not after it. A rough packaging concept reviewed with early device iterations catches conflicts, like a device geometry that makes tray loading awkward, while they’re still cheap to fix.
5. Could Another Manufacturer Successfully Build This Device?
This question is uncomfortable, which is exactly why it’s worth asking. Medical device design transfer readiness is a good proxy for how well a design and its documentation stand on their own, independent of any one team’s institutional knowledge.
Tooling ownership is the first thing to check. If molds, fixtures, or test equipment were built by a supplier and ownership and IP terms were never clearly documented, transferring to a new manufacturer, whether by choice or necessity, can turn into a negotiation that has nothing to do with engineering.
Process knowledge is harder to transfer because it often isn’t written down. Operators may know that a sub-assembly needs to be handled a certain way to avoid a defect that is never formally captured in a work instruction. That kind of knowledge is invisible until someone tries to replicate the process elsewhere and can’t.
Documentation quality is really the test of all of this. A complete design history file, current work instructions, validated process parameters, and inspection criteria specific enough for a new operator or facility to follow without guessing are what make a device portable. If replicating production depends on a phone call to someone who “just knows how it’s done,” that risk sits quietly in the program whether or not it’s ever triggered.
Portability matters even if a program never changes manufacturers, because it’s also what makes a second production line, a facility expansion, or a supplier’s business continuity plan work when needed. Asking “could someone else build this from what we’ve documented” during development is a useful forcing function to close those gaps before they become urgent.
6. Are We Paying for Performance We Don’t Actually Need?
Every design decision has a cost, and it’s easy for that cost to accumulate quietly through a series of individually reasonable choices, each a little more conservative than strictly necessary.
Cable and connector shielding is a common example. A fully shielded, foil-and-braid cable construction is the right call when a device is genuinely sensitive to EMI in its intended use environment. It’s a meaningfully more expensive and less flexible choice when applied by default to a signal that doesn’t need that level of protection. The same logic applies to material choices: a high-performance fluoropolymer jacket has real advantages in specific applications, but specifying it out of habit rather than requirement adds cost without adding value.
Tight tolerances deserve particular scrutiny because they compound. A tolerance tighter than function requires doesn’t just add inspection cost; it can reduce yield, since more parts fall outside spec even though they’d perform perfectly well. For any tight tolerance on a drawing, it’s worth asking what actually breaks if it were loosened slightly. Sometimes there’s a clear functional limit. Often it’s simply what a CAD default or an early prototype iteration happened to produce, carried forward without being revisited.
The question of custom versus standard components is the broader version of this question. A custom-molded connector housing might be technically superior to an off-the-shelf equivalent. Still, if the standard part meets the actual requirement, the custom option adds tooling cost, lead time, and a new point of supply chain risk for a performance margin the product doesn’t use.
None of this argues for under-engineering a device. It argues for tracing every performance specification back to an actual functional or clinical requirement, and for being honest about those set conservatively “to be safe” without a specific failure mode driving them. When done early, that review reliably reduces unit cost without affecting device performance.
7. Is Manufacturing Involved Early Enough?
This is the question underneath all the others. A design for manufacturability review conducted after the design is frozen can still catch problems, but by then the options for fixing them are narrower and more expensive. A DFM review conducted while the design is still fluid can shape decisions before they calcify into a drawing that has already undergone verification testing.
Supplier involvement follows the same logic. A supplier who sees a design early can often flag a manufacturability concern, a sourcing risk, or a cost driver that isn’t obvious from a drawing alone, because they’re looking at it through the lens of “how would I actually build a thousand of these” rather than “does this meet the spec.”
Cost-down opportunities are almost always larger and easier to capture early. Changing a material, tolerance, or process approach before tooling is in place is a drawing revision. Making the same change after tooling is in place and verification testing is complete is a much bigger undertaking. It often gets deprioritized because the cost of changing it now exceeds the savings it would produce.
Timeline reduction works the same way in reverse. Every manufacturability issue caught during design saves the time it would have taken to catch during process validation or, worse, during production ramp, when the fix has to happen under schedule pressure with inventory already committed.
The practical version is simple: bring a manufacturing partner, whether an internal team or a contract manufacturer, into the conversation before the design is frozen, not after. A short DFM review at each major design milestone costs a few hours. Discovering the same issues during process validation costs weeks, and during production ramp costs a great deal more than that.
Bringing It Together
None of these seven questions are complicated on their own. Can this be built at scale? Are we introducing supply chain risk? Are we ready for design changes? Have we planned for packaging and labeling? Could another manufacturer pick this up? Are we specifying more performance than we need? Is manufacturing in the room early enough?
What makes them worth asking systematically is that they catch different failure modes, none of which show up clearly on a bench prototype. A prototype tells you whether the device works. It doesn’t tell you whether it can be built consistently, sourced reliably, changed safely, packaged compliantly, transferred cleanly, or priced competitively. Those are separate questions, and they deserve attention throughout development, not one review gate right before launch.
The engineering teams that navigate this well share one habit: they treat medical device manufacturability as a design input from the earliest concept work, not a checklist applied at the end. That doesn’t mean slowing down. It usually means fewer surprises later, which is its own form of speed.
ClearPath Medical is a contract manufacturer of custom medical cable assemblies and other critical-to-care interconnect devices, and works through these questions with engineering teams throughout development, from early concept review through design transfer and production scale-up. If your program is heading toward a design freeze and you’d like a second set of eyes on manufacturability before you get there, that’s a conversation worth having early rather than after the prototype ships.
